Study protocol for a multicentre, prospective cohort study of the association of angiotensin II type 1 receptor blockers on outcomes of coronavirus infection
Introduction The COVID-19 epidemic grows and there are clinical trials of antivirals. There is an opportunity to complement these trials with investigation of angiotensin II type 1 receptor blockers (ARBs) because an ARB (losartan) was effective in murine influenza pneumonia.Methods and analysis Our...
Saved in:
| Main Authors: | Joel Singer, Srinivas Murthy, Bin Du, Terry Lee, Michael O Harhay, John C Marshall, Zhiyong Peng, James A. Russell, Arthur Slutsky, Dave Sweet, David M Patrick, Matthew Cheng, Kevin D Burns |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/10/12/e040768.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019
by: Marco Rossato, et al.
Published: (2020-07-01) -
The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
by: Myla E. Moretti, et al.
Published: (2012-01-01) -
Comparing recommended doses of angiotensin receptor blockers and ACE inhibitors (CORD Study)
by: J. Spinar, et al.
Published: (2009-08-01) -
Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01) -
Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)